Michael Straughen - Core Laboratories Executive
| CLB Stock | USD 15.33 0.07 0.45% |
Executive
Mr. Michael Straughen serves as Independent Member of the Board of Supervisory Directors of Core Laboratories N.V. He retired from executive office at the end of 2014 and now has various nonexecutive positions. He currently serves on the boards of Glacier, an Aberdeen based offshore services company the Glasgow based Denholm Oilfield Services Group and ASCO, an Aberdeen based logistics support group. He was also on the board of GMS PLC, an Abu Dhabi based but London listed, marine services company for three years until the end of 2016. Mr. Straughens last executive position was as an executive director of John Wood Group PLC, the UKs leading oilfield services business, from 2007 to end 2014, where he served as Chief Executive of the Engineering Division. His responsibilities included PL performance, HSSE, resourcing, customer relationships, strategy and growth. As an Executive Director of a publicly traded company, he also had responsibilities for corporate governance. From 1982 to 2007, he served in various roles, including as group managing director, with AMEC PLC, an international project management and engineering services provider. Mr. Straughen is a Chartered Engineer, has served on various industry bodies and is a mentor to small businesses. since 2019.
| Age | 71 |
| Tenure | 6 years |
| Address | 6316 Windfern Road, Houston, TX, United States, 77040 |
| Phone | 713 328 2673 |
| Web | https://www.corelab.com |
Latest Insider Transactions
Core Laboratories Management Efficiency
The company has Return on Asset of 0.0553 % which means that on every $100 spent on assets, it made $0.0553 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1319 %, implying that it generated $0.1319 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At present, Core Laboratories' Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.1, whereas Return On Tangible Assets are forecasted to decline to 0.06. At present, Core Laboratories' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 236.2 M, whereas Total Assets are forecasted to decline to about 553.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mike Loucaides | NOV Inc | N/A | |
| William Maxwell | Oil States International | N/A | |
| Emily Shields | MRC Global | 49 | |
| Ian Eckert | Natural Gas Services | 37 | |
| Mark CFA | RPC Inc | N/A | |
| William Merz | Oceaneering International | N/A | |
| Dan Pratt | Now Inc | N/A | |
| Shweta KurveyMishra | MRC Global | 45 | |
| Ellen Pennington | Oil States International | N/A | |
| Sharon Gardner | RPC Inc | N/A | |
| Dawn Smith | Cactus Inc | N/A | |
| John McCarthy | MRC Global | 59 | |
| Monica Broughton | MRC Global | N/A | |
| Brad Wise | Now Inc | N/A | |
| John Bittner | Natural Gas Services | 56 | |
| Preet Dhindsa | Enerflex | N/A | |
| John Rowell | Natural Gas Services | N/A | |
| Stuart Stavley | Bristow Group | 53 | |
| Robert Mitchell | Enerflex | N/A | |
| Alina Parast | ChampionX | N/A | |
| Mary Wersebe | Bristow Group | 49 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0553 |
Core Laboratories Leadership Team
Elected by the shareholders, the Core Laboratories' board of directors comprises two types of representatives: Core Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Core. The board's role is to monitor Core Laboratories' management team and ensure that shareholders' interests are well served. Core Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Core Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gwendolyn MBA, Senior Relations | ||
| J Dumas, Vice President Business Development | ||
| Martha Carnes, Presiding Non-Executive Lead Independent Member of the Supervisory Board | ||
| Lawrence Bruno, Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer | ||
| Monique Eeuwijk, Non-Executive Independent Member of the Supervisory Board | ||
| Kevin Daniels, Vice President, Chief Accounting Officer | ||
| Jacobus Schouten, Managing Director | ||
| Christopher Hill, Chief Financial Officer, Senior Vice President | ||
| Kwaku Temeng, Non-Executive Independent Member of the Supervisory Board | ||
| Sow Teo, Treasurer VP | ||
| Gregory Barnett, Non-Executive Independent Member of the Supervisory Board | ||
| Margaret Kempen, Independent Member of the Board of Supervisory Directors | ||
| Mark Tattoli, Senior Vice President General Counsel, Secretary | ||
| Mark Elvig, Senior Vice President, Secretary, and General Counsel | ||
| Harvey Klingensmith, Non-Executive Independent Member of the Supervisory Board | ||
| Michael Straughen, Non-Executive Independent Member of the Supervisory Board | ||
| Gwendolyn Gresham, Senior Vice President Corporate Development and Investor Relations | ||
| Leslie Linklater, Organization, People | ||
| Billy Anthony, President Tools |
Core Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Core Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0553 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 878.84 M | ||||
| Shares Outstanding | 46.83 M | ||||
| Shares Owned By Insiders | 0.95 % | ||||
| Shares Owned By Institutions | 99.05 % | ||||
| Number Of Shares Shorted | 6.47 M | ||||
| Price To Earning | 101.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.896 | Dividend Share 0.04 | Earnings Share 0.66 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.